Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | CRHBP | P24387 | 1/20 | 0.52 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2094772 | 0.94 | KMT2A (0.50) | KMT2AKDM4EMEN1ALDH1A1MAPK1 | |
| SCHEMBL1600111 | 0.88 | KMT2A (0.65) | KMT2AKDM4EMEN1ALDH1A1MAPK1 | |
| SCHEMBL16884151 | 0.85 | GAA (0.63) | KMT2AKDM4EMEN1ALDH1A1MAPK1 | |
| SCHEMBL9397288 | 0.84 | SIGMAR1 (0.63) | SIGMAR1 | |
| SCHEMBL28191613 | 0.83 | GAA (0.66) | KMT2AKDM4EMEN1ALDH1A1MAPK1 | |
| SCHEMBL18182316 | 0.82 | MAPK1 (0.72) | KMT2AKDM4EMEN1ALDH1A1MAPK1 | |
| SCHEMBL26113758 | 0.82 | KMT2A (0.56) | KMT2AKDM4EMEN1ALDH1A1MAPK1 | |
| SCHEMBL8308417 | 0.82 | KDM4E (0.67) | KMT2AKDM4EMEN1ALDH1A1ALOX15 | |
| SCHEMBL4324560 | 0.81 | CYP1A2 (0.57) | KMT2AKDM4EMEN1ALDH1A1MAPK1 | |
| SCHEMBL13886164 | 0.81 | CRHBP (0.73) | KMT2AKDM4EMEN1ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| US-3959281-A | CORONARY DILATORS | CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) | 1976-05-25 | — | — | US | claimed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | disclosed |
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |
| EP-0903346-A1 | SYDNONE IMINE DERIVATIVES | Chugai Seiyaku Kabushiki Kaisha (JP) | 1999-03-24 | — | — | EP | disclosed |
| US-5340811-A | Bronchodilator agent | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JP) | 1994-08-23 | — | — | US | disclosed |
| EP-0471841-A1 | SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1992-02-26 | — | — | EP | disclosed |
| US-4533554-A | ANALGESICS, HYPOTENSIVE AGENTS, ANTI-INFLAMMATORY AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-08-06 | — | — | US | disclosed |
| US-4388312-A | HYPOTENSIVE AGENTS, ANTIALLERGENS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1983-06-14 | — | — | US | disclosed |
| EP-0025692-B1 | QUINONE DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1982-12-01 | — | — | EP | disclosed |
| EP-0025692-A1 | Quinone derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1981-03-25 | — | — | EP | disclosed |
| US-3855225-A | BASICALLY SUBSTITUTED (1H,3H)-QUINAZOLINE-2-THION-4-ONE DERIVATIVES | CASSELLA FARBWERKE MAINKUR AG | 1974-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | KMT2A 3324/4885KDM4E 4578/4885MEN1 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.